{"entity":{"id":"mesna","kind":"drug","name":"Mesna","aka":["Uromitexan","Sodium 2-mercaptoethanesulfonate"],"tldr":"Mesna is given with the chemotherapy ifosfamide (and high-dose cyclophosphamide) to stop its breakdown products from burning the bladder lining and causing bleeding.","summary":"Mesna was approved in December 1988 as a prophylactic agent to reduce the incidence of ifosfamide-induced haemorrhagic cystitis, with oral tablets approved in 2002 allowing intravenous-then-oral schedules; it is given with every ifosfamide dose (sarcoma, germ cell, lymphoma regimens such as ICE and VeIP) and with high-dose cyclophosphamide in transplant conditioning. The label notes it does not prevent haematuria from other causes such as thrombocytopenia. Hypersensitivity reactions, including rare severe skin reactions, and false-positive urine ketone tests are the practical issues; nausea and headache are common.","status":"approved","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Mesna","links":[{"label":"US label (DailyMed)","url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=mesna"},{"label":"NCI drug page","url":"https://www.cancer.gov/about-cancer/treatment/drugs/mesna"}],"tags":["nci-list","supportive","generic"],"related":["ifosfamide","cyclophosphamide"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["baxter"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07255664","nct06119685"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"brand":"Mesnex","modality":"Uroprotective thiol","supportive":true,"mechanism":"Free thiol excreted in urine that binds and detoxifies acrolein and 4-hydroxy-ifosfamide, the urotoxic metabolites of ifosfamide and cyclophosphamide, in the bladder.","approvals":[{"region":"US","year":1988,"indication":"Prophylaxis of ifosfamide-induced haemorrhagic cystitis (oral tablets 2002)"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/mesna/","neighbours":{"drug":[{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"ifosfamide","kind":"drug","name":"Ifosfamide","route":"/drugs/ifosfamide/"}],"company":[{"id":"baxter","kind":"company","name":"Baxter International","route":"/companies/baxter/"}],"trial":[{"id":"nct07255664","kind":"trial","name":"A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC","route":"/trials/nct07255664/"},{"id":"nct06119685","kind":"trial","name":"IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers","route":"/trials/nct06119685/"}]}}